Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated. Among 25,531 participants in the National Health and Nutrition Examination Survey (NHANES) from 2015 to.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease. Muvalaplin is a small molecule inhibitor that prevents the.
Frontiers in Cardiovascular Medicine
NOVEMBER 17, 2024
IntroductionA direct causal link between Sudden Cardiac Death (SCD) and COVID-19 is unproven, although current data suggest a plausible association.AimThis study aims to map and analyze the intersection of research on sudden cardiac death and COVID-19 through a comprehensive bibliometric analysis.MethodologyThis study searched the literature by applying the keywords “COVID-19” AND “Sudden Cardiac Death (SCD)”.
HCPLive
NOVEMBER 17, 2024
Obesity-related ischemic heart disease deaths rose from 1999 to 2020, particularly in middle-aged men and Black adults, per CDC WONDER data.
Med Page Today
NOVEMBER 19, 2024
(MedPage Today) -- Genetic risk for Alzheimer's disease and dementia appeared to be partly offset by high levels of cardiorespiratory fitness, U.K. Biobank data suggested. Overall, high cardiorespiratory fitness was associated with better global.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had.
Nature Reviews - Cardiology
NOVEMBER 18, 2024
Nature Reviews Cardiology, Published online: 19 November 2024; doi:10.1038/s41569-024-01105-y Large language models represent a transformative leap in artificial intelligence and natural language processing, offering exciting potential across cardiology, from clinical care to education and research. However, several crucial challenges limit the practical implementation of large language models in cardiology.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. Incident.
American Heart News - Heart News
NOVEMBER 16, 2024
Research Highlights: A new, multicenter study demonstrated that ablation treatment may be a better first option than medication for many heart attack survivors who develop abnormal electrical short circuits in their heart, which are episodes of.
Dr. Smith's ECG Blog
NOVEMBER 17, 2024
Written by Willy Frick A 51 year old man with hypertension presented with three hours of acute onset, severe midsternal chest pain associated with two episodes of nausea and vomiting. ECG 1 What do you think? Smith : Inferior leads have subtle ST Elevation with reciprocal STD in aVL. The end of the T-wave in all of II, III, aVF has a rapid downturn, suggesting early T-wave inversion.
HCPLive
NOVEMBER 17, 2024
Oussama Wazni, MD, discusses the results of the OPTION trial examining LAAC in atrial fibrillation as well as its reception as AHA 2024.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- Secondhand permanent pacemaker use in poorer countries, following thorough cleaning and repackaging, has not resulted in patient harm so far, according to the My Heart Your Heart trialists. In patients who could.
American Heart News - Heart News
NOVEMBER 17, 2024
Research Highlights: The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart attack or stroke. More research is needed to further.
Dr. Smith's ECG Blog
NOVEMBER 19, 2024
These ECGs were texted to me by one of our previous ultrasound fellows, Will Smoot An elderly male arrived via EMS for acute substernal chest pain with radiation to left shoulder and arm that awakened him from sleep at 0030. He took two full strength aspirin prior to EMS arrival. The pain was relieved by one prehospital NTG spray. He arrived at the ED just shy of two hours after onset, pain free.
HCPLive
NOVEMBER 16, 2024
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.
Med Page Today
NOVEMBER 19, 2024
(MedPage Today) -- After a certain threshold, cumulative opioid use was associated with higher dementia risk, a study of adults over age 60 in Denmark showed. In a nested case-control study, opioid use above 90 total standardized doses (TSDs.
American Heart News - Heart News
NOVEMBER 17, 2024
Research Highlights: An electronic message to "nudge" patients to get a flu vaccine highlighting the cardiovascular benefits of flu shots improved vaccination rates among more than two million adults in three clinical trials in Denmark. The research.
American College of Cardiology
NOVEMBER 16, 2024
More time spent sitting, reclining or lying down during the day may increase the risk of cardiovascular disease and death, according to a study presented at AHA 2024 and simultaneously published in JACC.
HCPLive
NOVEMBER 17, 2024
Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.
Med Page Today
NOVEMBER 17, 2024
(MedPage Today) -- CHICAGO -- A mineralocorticoid receptor antagonist (MRA) was unable to further improve 3-year outcomes of acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial. Among heart attack survivors without.
Science Daily - Heart Disease
NOVEMBER 18, 2024
A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation) in healthy adults in comparison to the oral and intravenous forms of the medication. The existing oral and intravenous forms of bumetanide are commonly prescribed for people with heart failure because they ease tissue swelling, a common cause of symptoms for people with heart failure.
American College of Cardiology
NOVEMBER 19, 2024
American Society of Echocardiography (ASE) guidelines for echocardiographic evaluation of aortic regurgitation (AR) were found to “display very good performance†in detecting significant AR, according to a study published Nov. 13 in JACC: Cardiovascular Imaging.
HCPLive
NOVEMBER 19, 2024
Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.
Med Page Today
NOVEMBER 19, 2024
(MedPage Today) -- Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk of heart failure, a randomized.
JAMA Cardiology
NOVEMBER 16, 2024
This multicenter secondary analysis of the FINEARTS-HF randomized clinical trial examines the treatment effect of finerenone, relative to placebo, on clinical outcomes based on postrandomization potassium levels.
American College of Cardiology
NOVEMBER 16, 2024
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
HCPLive
NOVEMBER 18, 2024
Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.
Med Page Today
NOVEMBER 20, 2024
(MedPage Today) -- CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less likely to have a greater than.
JAMA Cardiology
NOVEMBER 16, 2024
This prespecified secondary analysis of a randomized clinical trial examines the efficacy and safety of finerenone in women and men with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction.
American College of Cardiology
NOVEMBER 18, 2024
Zerlasiran, a short-interfering RNA, was well-tolerated and reduced time-averaged lipoprotein(a) [Lp(a)] concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic cardiovascular disease (ASCVD).
HCPLive
NOVEMBER 17, 2024
Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.
Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- CHICAGO -- For patients with ventricular tachycardia (VT) and ischemic cardiomyopathy, going right to catheter ablation improved outcomes compared with trying antiarrhythmic drugs first, the VANISH2 trial showed. Death or.
American Heart News - Heart News
NOVEMBER 17, 2024
Research Highlights: A study of three pills that combined two types of blood-pressure-lowering medications into one pill found that all combinations worked equally well among adults in India. Results from the TOPSPIN trial found that any.
Science Daily - Heart Disease
NOVEMBER 18, 2024
Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining how industrially produced trans-unsaturated fatty acids in our food significantly promote ASCVD and encouraging lawmakers to impose regulations on the use of these fats in food.
HCPLive
NOVEMBER 20, 2024
In these guidelines compiled by the ACAAI, the AAAAI, and the AAOA, recommendations are provided to insurance companies for documentation needed for allergen immunotherapy.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- WASHINGTON -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) may not have to worry so much about increased cardiovascular risk -- if they're taking statins, research presented here suggested.
American Heart News - Heart News
NOVEMBER 17, 2024
Research Highlights: The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries involving bypass did not result in significant benefits at preventing death, stroke or organ injury.
Expert insights. Personalized for you.
119 
Let's personalize your content